(Q53852671)

21 May 2018

title

Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. (English)

1 reference

21 May 2018

0 references

1 reference

2

Alexandra Schäfer

1 reference

21 May 2018

author name string

Brian P Doehle

series ordinal

1

1 reference

21 May 2018

Bryan R Cullen

series ordinal

3

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 September 2005

1 reference

21 May 2018

published in

Virology

1 reference

21 May 2018

volume

339

1 reference

21 May 2018

issue

2

1 reference

21 May 2018

page(s)

281-288

1 reference

21 May 2018

Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Intrinsic immunity: a front-line defense against viral attack

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Cytidine deamination of retroviral DNA by diverse APOBEC proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

The interaction between HIV-1 Gag and APOBEC3G.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

APOBEC3G targets specific virus species.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

New strategies in the treatment of the thalassemias.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

HIV-1 Vif Blocks the Antiviral Activity of APOBEC3G by Impairing Both Its Translation and Intracellular Stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Induction of APOBEC3G Ubiquitination and Degradation by an HIV-1 Vif-Cul5-SCF Complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

APOBEC3G incorporation into human immunodeficiency virus type 1 particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

Role of Vif in human immunodeficiency virus type 1 reverse transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.06.005

1 reference

21 May 2018

1 reference

21 May 2018